TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Investing.com - Syros Pharma reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Syros Pharma announced earnings per share of $-3.210 on revenue of $3.9M. Analysts polled by Investing.com EPS of $-3.880 on revenue of $5.18M.
Syros Pharma 's are down 19.03% and is trading at $4.100 , still down 90.83% from its 52 week high of $43.40 set on Monday, November 15, 2021.
Syros Pharma shares gained 3.02% to trade at $4.100 in pre-market trade the report.
Syros Pharma follows other major Healthcare sector earnings this month
Syros Pharma's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar